Comparison
3 Methylglutaconic Aciduria Type 2 C0574083 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between 3 Methylglutaconic Aciduria Type 2 and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 2 C0574083
Also called Barth syndrome, this genetic condition primarily affects males and impairs mitochondrial function. It causes heart muscle weakness, muscle weakness, and recurrent infections. Treatment includes cardiac care, infection prevention, and supportive therapies.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 2 C0574083
0-5
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 2 C0574083
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 2 C0574083
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 2 C0574083
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-2-C0574083 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 2 C0574083 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Cardiac involvement | Cardiomyopathy or heart-muscle weakness is a core reported feature and may appear in early childhood. | Heart disease is not a defining feature in the supplied description. | High |
| Development and learning | Developmental effects may occur, but the supplied focus is metabolic, cardiac, and muscular disease. | Developmental delay, learning challenges, and sometimes distinctive facial features are characteristic. | High |
| Infection pattern | Recurrent infections are described and may reflect neutropenia or immune vulnerability; confirmation is clinical. | Recurrent infection is not established as a core feature from the supplied source. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 2 C0574083 when
Male infant or child with cardiomyopathy plus muscle weakness
This combination fits the supplied Barth syndrome profile better than a chromosomal duplication syndrome.
High
Abnormal organic-acid findings suggesting 3-methylglutaconic aciduria
A metabolic result supports further evaluation for type 2 disease, but the result alone is not a diagnosis.
Moderate
Recurrent infections with suspected neutropenia
Infection susceptibility is described in Barth syndrome and warrants clinician-directed hematologic assessment.
Moderate
Choose 17p11 2 Microduplication Syndrome C2931246 when
Developmental delay with learning difficulties and suggestive facial features
These features align with the supplied description of 17p11.2 microduplication syndrome.
High
Chromosomal microarray shows a 17p11.2 duplication
A confirmed duplication supports this diagnosis; interpretation should include size, genes, and clinical correlation.
High
No dominant cardiomyopathy or metabolic crisis
Absence of those features makes Barth syndrome less likely, though it does not exclude other conditions.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 2 C0574083 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show elevated 3-methylglutaconic acid and related metabolites; exact cutoffs are not supplied. | No characteristic organic-acid abnormality is established from the source. | An abnormal result suggests a metabolic disorder but requires genetic and clinical confirmation. |
| Genetic testing | TAFAZZIN-related testing may confirm Barth syndrome when clinically indicated. | Chromosomal microarray or equivalent testing may identify a 17p11.2 duplication. | The tests target different mechanisms and should be chosen from the phenotype. |
| Cardiac evaluation | Echocardiography or cardiology assessment may reveal cardiomyopathy or ventricular dysfunction. | Routine cardiac abnormality is not established by the supplied description. | Cardiac findings strongly favor Barth syndrome but do not replace genetic confirmation. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 2 C0574083
- Outcome
- Often severe and lifelong, with outcome strongly influenced by cardiac disease and infections; exact mortality is not stated.
- Factors
- Cardiomyopathy severity, infection susceptibility, nutrition, and access to specialist care.
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Generally described as moderate and chronic, with variable developmental and learning outcomes.
- Factors
- Duplication extent, developmental profile, comorbidities, and early support services.
Time frame: Both are chronic; Barth features often emerge from birth to early childhood, while duplication features may be recognized across childhood.
Prognosis should be individualized; these sources do not establish exact survival or functional outcomes.
Complications comparison
| Complication | Presentation |
|---|---|
| Heart failure or arrhythmia | A major potential complication because cardiomyopathy is central. Not established as typical from the supplied source. Cardiac surveillance is especially relevant for suspected Barth syndrome. |
| Serious infection | Recurrent or severe infection may occur and needs prompt assessment. Not described as a defining complication. Infection risk should be individualized rather than assumed. |
| Learning and behavioral needs | May occur but are not the main supplied features. Developmental delay and learning challenges are expected areas of need. Educational and developmental support is central for the duplication syndrome. |
Patient education highlights
- HighDifferent causes
One condition is a mitochondrial gene disorder; the other is a chromosomal duplication. Family implications differ and require genetic counseling.
- HighWarning symptoms
For suspected Barth syndrome, seek urgent care for breathing difficulty, poor feeding, fainting, or signs of serious infection.
- MediumSupportive care
Management is individualized. Cardiac care, infection prevention, therapies, and educational support may be used; no doses are specified here.